PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
| (a) | Provectus Biopharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June 27, 2018. |
| (b) | At the Annual Meeting, the Company’s stockholders voted on three proposals. A brief description and tabulation of votes for each proposal are set forth below. |
Proposal 1. The Company’s stockholders elected the following directors for a term of one year at the Annual Meeting, consistent with the recommendation of the Company’s board of directors (the “Board”). There were 198,013,162 broker non-votes with respect to the proposal.
| Nominee | For | Withheld |
| Bruce Horowitz | 101,385,126 | 6,712,402 |
| Jan Koe | 100,539,944 | 7,557,584 |
| John Lacey, III, M.D. | 104,399,706 | 3,697,822 |
| Ed Pershing, CPA | 104,393,513 | 3,704,015 |
| Dominic Rodrigues, CFA | 103,970,701 | 4,126,827 |
Proposal 2. The Company’s stockholders approved the advisory vote on the compensation of the Company’s named executive officers at the Annual Meeting, consistent with the Board’s recommendation. There were 198,013,162 broker non-votes with respect to the proposal.
| For | Against | Abstain |
| 98,885,487 | 8,525,139 | 686,902 |
Proposal 3. The Company’s stockholders ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for 2018 at the Annual Meeting, consistent with the Board’s recommendation. There were no broker non-votes with respect to the proposal.
| For | Against | Abstain |
| 298,348,783 | 13,214,232 | 1,823,220 |
About PROVECTUS BIOPHARMACEUTICALS, INC. (OTCMKTS:PVCT)
Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.
